Promising results for drug candidate CS1

Jul 13

1 min read

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with drug candidate CS1 maintained or improved their functional and biomarker status, and that CS1 showed a favourable safety and tolerability profile. A Phase IIb trial for CS1 begins this summer.

Read the Cereno Scientific press release

Recent Posts

Frequent imaging of children with PH may lead to high radiation doses

A 41-study review of children with non-cancer chronic diseases looked at how much radiation they were exposed to during their relatively frequent medical imaging. Children with PH were included. The r

What affects physical activity for people with PH?

A UK study examined the factors that affected physical activity participation among people with pulmonary hypertension (PH). They found four themes: fear of breathlessness; lack of motivation and a de

Why men with systemic sclerosis-associated PAH fare worse

Men with systemic sclerosis and pulmonary arterial hypertension (PAH) tend to have more heart-related complications and lower survival rates. Differences in the effects of hormones such as estrogen an

1 Comment

berka2013

Sep 15

The BTC is aimed at people who are curious about Bitcoin and blockchain but prefer explanations written in plain language.